← All trials
NCT04893759
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2021
- Primary completion
- Oct 1, 2023
- Completion date
- Dec 31, 2024
- First posted
- May 19, 2021
- Last posted
- Nov 8, 2021
- Enrollment
- 60
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ascentage Pharma Group Inc.Lead sponsor
- Fudan UniversityOverall official - principal investigator
- Sun Yat-Sen UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.